AbbVie sponsored the study. Dr. Poordad has received research support and acted as a consultant to the company. He also disclosed receiving grants or research support or acting as an adviser or speaker for Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline, in addition to others.
Conference Coverage
All-oral, triple-acting HCV regimen cures more than 90% of cirrhotic cases
More Liver Disease News
- Short-Course Vasoconstrictors After EVL: Time for a New Standard of Care?
- MASH: Experts Offer Noninvasive Cutoffs for Prescribing Resmetirom
- Can We Repurpose Obesity Drugs to Reverse Liver Disease?
- Giving the Smallest GI Transplant Patients a New Lease On Life
- MASLD Healthcare Costs Climbing Fast in Canada
- AI-Assisted Pathology Poised to Transform Liver Disease Care
- Baveno VI Criteria Appear Cost-Effective for Detecting Varices in Cirrhosis
- Alcohol-Associated Liver Disease’s Changing Demographics
Question 1 of 5